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The editors of Contemporary Issues in Women’s
Health solicit reporters and correspondents from
throughout the world to make contributions to this
section. Please feel free to e-mail or otherwise con-
tact Dr. Timothy Johnson at trbj@umich.edu or
Prof. S. Arulkumaran at s.arulkumaran@sghms.
ac.uk if you have reports or stories that you would
like to have included. We would be happy to attrib-
ute the items to those reporters and correpondents
who give permission in their transmittal. Other-
wise, we will share those reports that we think are
of the greatest interest to our readership without
attribution.
More concern about the health of Afghanistan
women
The New York Times on October 27, 2002
reported that women continue to suffer in the cur-
rent Afghan health crisis. The most comprehensive
survey of medical facilities and maternal deaths
every conducted in Afghanistan shows that the
country’s 25 million people have among the
world’s worst health and highest maternal mortal-
ity, described as ‘a catastrophic maternal mortality
rate, possibly the worst in the world’. President
Hamid Karzai and Tommy G. Thompson, the Unit-
ed States Secretary of Health and Human Services,
both voiced their concern. Other data from the
maternal heath study showed that half the women
of reproductive age died of complications of child-
birth. In one remote province, 64 percent of deaths
of reproductive age women were pregnancy-relat-
ed. The study was supervised by the Environmen-
tal Committee of Physicians with the Centers for
Disease Control and Prevention in the U.S. As
always, education, access to primary health care,
and access to service are major issues. Only 4 per-
cent of those who died were literate, and only 30
percent had access to radio where health and
hygiene principles can be disseminated.
A major concern was that the United States
would forget Afghanistan, as it did after the Sovi-
ets left in 1989, as well as because of the distrac-
tions of Iraq and the war on terrorism. Mr.
Thompson said that he was shocked by the chal-
lenges facing Afghanistan’s women, and he there-
fore signed a cooperative agreement with the
Afghan Health Ministry. We shall see where this
new initiative leads. These issues are not new to
obstetricianygynecologists but should certainly be
an ongoing part of our consciousness and our
actions.
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Nonoxynol-9 fails to prevent HIV
According to an important article in Lancet, the
effectiveness of COL-1492, a nonoxynol-9 vaginal
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gel, was tested in a randomized trial to assess
effectiveness verses placebo in prevention of HIV.
The study demonstrated no benefit, and nonoxy-
nol-9 actually increased the risk of HIV infection
when compared to placebo in a group of 892
female sex workers from Benin, Cote d’lvoire,
South Africa and Thailand. (Adjusted relative risk
1.5; 95% Cl 1.0–2.2; Ps0.047). It appears that
the use of nonoxynol-9 by these high risk women
increases risk of HIV transmission secondary to
vaginal ulcerations and other genital lesions. As
articulated at the subsequent WHOyCONRAD
meeting in Geneva, nonoxynol-9 should not be
used to promote the prevention of HIV or sexually
transmitted infections: condoms are the method of
choice. As the editors mentioned (Lancet
360:962–963, 2002) ‘these are not the advances
that are wanted in the fight against HIV and STD.’
This study at least gives us a definitive answer on
nonoxynol-9, and we ought to be encouraged that
this large randomized clinical trial provides defin-
itive evidence to be used in pubic policy and
patient education. Unfortunately as has become a
theme in the column, this is yet another example
in Obstetrics and Gynecology where new techno-
logic interventions that were widely accepted and
adopted have been shown by randomized clinical
trials to have no benefit. We agree that ‘Such trials,
despite their cost and complexity, should be done
sooner rather than later in product development’.
We anticipate more reports on this topic and will
make note of them in this column.
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Salpingo-oophorectomy in the prevention of
ovarian and breast cancer in high risk patients
Important studies on the role of salpingo-oopho-
rectomy in women with BRCA1 or BRCA2 muta-
tions were published in the New England Journal
of Medicine in May 2002. These articles suggested
that prophylactic oophorectomy in carriers of
BRCA1 or BRCA2 reduced both the risk of ovar-
ian cancer and breast cancer. These provocative
studies should not lead to an immediate change in
practice but, rather, to a careful consideration of
the implications of this approach. For a long time,
women with high risk of ovarian cancer, especially
familial risks, have been undergoing this therapy.
The beneficial results in terms of breast cancer
mortality from the current studies were unexpected
and surprising. This is an important area that we
must continue to watch. It is clear that molecular
genetics needs to be understood by clinical obste-
tricianygynecologists and that in the very near
future concepts from molecular genetics will guide
our therapy and practice.
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Self breast exam: dogma disputed
Once again, we draw our readers’ attention to
an article from a developing county that may affect
clinical practice. There is news from China with
regard to a randomized trial that is similar to our
report on the Magpie Trial in a previous edition of
Contemporary Issues (Int J Gynecol Obstet 78:3–
5, 2002), which showed the benefit of magnesium
sulfate in the management of preeclampsia (Lancet
359:1877–1890, 2002). Now, a report from China
of a well-designed, large randomized multicenter
international trial shows that a common western
practice, self breast examination, provides no ben-
efit to the patients. In over 266,000 women
enrolled, initial instruction in self breast exam fol-
lowed by reinforcement sessions and breast self
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exam under medical supervision showed no
improvement in mortality from breast cancer in the
period from October 1989 to October 1991. How-
ever more non-breast lesions were diagnosed in the
instruction group than the control group leading to
more interventions. The conclusion was that inten-
sive instruction in breast self examination did not
reduce mortality from breast cancer. The authors
suggest that breast self examination programs
would be unlikely to reduce mortality from breast
cancer in the absence of mammography. Women
who choose to practice breast self examination
should be informed of its lack of efficacy and that
it may in fact increase their chance of having a
benign breast biopsy. While this information is not
new, the high quality of the study, so large that it
will probably never be replicated, will significantly
dampen enthusiasm for self breast examination. In
the accompanying editorial, we are reminded that
women should be encouraged to seek medical
attention when they incidentally discover breast
lumps but that self awareness through self exami-
nation may have an increased impact in terms of
anxiety, hopeless perceptions and unnecessary and
unhelpful interventions, although there may be a
positive effect in the reduction in the stage of pres-
entation of many subsequent breast cancers.
This is an interesting study and is similar to oth-
er observation in the practice of obstetrics. Many
years ago, the randomized trial of routine fetal
movement counting showed no benefit in large
populations. Extrapolations and comparisons to
other self examination practices (even to men and
the recommendation for routine self testicular
examination) are appropriate. This is an example
of a research report that provides important results
for women and carries important implications for
both sexes.
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